Vikas Gupta, CEO and Chief Investment Strategist at OmniScience Capital, said he would avoid technology stocks due to uncertain fundamental prospects amid the impact of AI. He also believes the sector is overvalued given the outlook. He remains cautious on pharma as well, citing overvaluation.
